Engraftment


Major criteria

Minor criteria

T ≥ 38.3 °C with no identifiable infectious etiology

Hepatic dysfunction with either total bilirubin ≥ 2 mg/dL or transaminase levels ≥ 2x ULN

Erythrodermatous rash involving > 25 % BSA and not attributable to a medication

Renal insufficiency (SCr ≥ 2x baselines)

Noncardiogenic pulmonary edema, manifested by diffuse pulmonary infiltrates consistent with the diagnosis of hypoxia

Weight gain ≥ 2.5 % of baseline body weight

Transient encephalopathy unexplained by other causes


BSA body surface area, ULN upper limit of normal, SCr serum creatinine





a.

The diagnosis of ES is made when a patient develops all three major criteria or two major and at least one minor criterion within 96 h of engraftment .

 


 


6.

This syndrome is often self-limited, resolving with discontinuation of growth factors:



a.

In more severe cases with symptomatic pulmonary involvement, corticosteroids (1 mg/kg/day) have been shown to decrease mortality.

 

b.

Additionally, C1 esterase inhibitor concentrates have been shown to improve outcome in small studies .

 

 





14.4 Foundation for the Accreditation of Cellular Therapy Standards for Review of Engraftment


The major objective of Foundation for the Accreditation of Cellular Therapy (FACT) is to promote quality medical and laboratory practice in HSCT and other therapies using cellular products. FACT Standards were formed from laboratory standards developed by the International Society for Cellular Therapy (ISCT) and from the clinical and training guidelines developed by the American Society of Blood and Marrow Transplantation (ASBMT). Consensus in medical literature and contributions of experts in the cellular therapy field also led to the development of the standards:



1.

FACT standards define engraftment as “the reconstitution of recipient hematopoiesis with blood cells and platelets from a donor”. The standards require:



a.

Policies and procedures to describe the review of time to engraftment by the collection facility, processing facility, and clinical transplant program following cellular therapy product administration.

Only gold members can continue reading. Log In or Register to continue

Stay updated, free articles. Join our Telegram channel

Jun 23, 2017 | Posted by in HEMATOLOGY | Comments Off on Engraftment

Full access? Get Clinical Tree

Get Clinical Tree app for offline access